Literature DB >> 24062151

[Tear in the retinal pigment epithelium by intravitreal injection of aflibercept].

T Bertelmann1, W Sekundo, Y Wenner.   

Abstract

Development of tears in the retinal pigment epithelium (RIP) has been described as a possible complication following anti-vascular endothelial growth factor (VEGF) antibody therapy with substances which have been available for years when treating pigment epithelium detachment (PED) in eyes affected by age-related macular degeneration (AMD). Aflibercept has become available for the treatment of exsudative AMD since December 2012. This case report describes a further patient in addition to the only other case published so far who developed RIP after aflibercept treatment for PED. Patients have to be thoroughly informed about this potential side effect before initiation of intravitreal aflibercept injection therapy.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24062151     DOI： 10.1007/s00347-013-2954-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  16 in total

1.  A new grading system for retinal pigment epithelial tears.

Authors:  David Sarraf; Shantan Reddy; Allen Chiang; Fei Yu; Atul Jain
Journal:  Retina       Date:  2010 Jul-Aug       Impact factor: 4.256

Review 2.  [Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options].

Authors:  A Lommatzsch
Journal:  Ophthalmologe       Date:  2010-12       Impact factor: 1.059

3.  Quantification of retinal pigment epithelium tear area in age-related macular degeneration.

Authors:  Christoph R Clemens; Florian Alten; Christine Baumgart; Peter Heiduschka; Nicole Eter
Journal:  Retina       Date:  2014-01       Impact factor: 4.256

4.  Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.

Authors:  Clement K Chan; Prema Abraham; Carsten H Meyer; Gregg T Kokame; Peter K Kaiser; Michael E Rauser; Jeffrey G Gross; Asha S D Nuthi; Steven G Lin; Noha S Daher
Journal:  Retina       Date:  2010-02       Impact factor: 4.256

5.  Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy.

Authors:  David Sarraf; Clement Chan; Ehsan Rahimy; Prema Abraham
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

6.  RPE tears after pegaptanib treatment in age-related macular degeneration.

Authors:  Louis K Chang; Christina J Flaxel; Andreas K Lauer; David Sarraf
Journal:  Retina       Date:  2007-09       Impact factor: 4.256

7.  Prediction of retinal pigment epithelial tear in serous vascularized pigment epithelium detachment.

Authors:  Christoph R Clemens; Nina Bastian; Florian Alten; Carolin Milojcic; Peter Heiduschka; Nicole Eter
Journal:  Acta Ophthalmol       Date:  2013-07-02       Impact factor: 3.761

8.  Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.

Authors:  Clement K Chan; Carsten H Meyer; Jeffrey G Gross; Prema Abraham; Asha S D Nuthi; Gregg T Kokame; Steven G Lin; Michael E Rauser; Peter K Kaiser
Journal:  Retina       Date:  2007-06       Impact factor: 4.256

9.  Fundus autofluorescence and spectral-domain optical coherence tomography findings suggesting tissue remodelling in retinal pigment epithelium tear.

Authors:  Albert Caramoy; Sascha Fauser; Bernd Kirchhof
Journal:  Br J Ophthalmol       Date:  2012-07-23       Impact factor: 4.638

10.  Retinal pigment epithelium tear after intravitreal aflibercept injection.

Authors:  Masaaki Saito; Mariko Kano; Kanako Itagaki; Yasuharu Oguchi; Tetsuju Sekiryu
Journal:  Clin Ophthalmol       Date:  2013-06-26
View more
  3 in total

1.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).

Authors:  David Sarraf; Anthony Joseph; Ehsan Rahimy
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 3.  MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Paul Mitchell; Francisco J Rodríguez; Antonia M Joussen; Adrian Koh; Nicole Eter; David T Wong; Jean-François Korobelnik; Annabelle A Okada
Journal:  Retina       Date:  2021-04-01       Impact factor: 3.975
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.